{'fraction_non_alphanumeric': 0.03744798890429958, 'fraction_numerical': 0.018030513176144243, 'mean_word_length': 5.504504504504505, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Colchicine in the management of mucous membrane pemphigoid

Mucous membrane pemphigoid (MMP) usually runs a chronic and potentially devastating course. Its management requires long‐term oral corticosteroids. Safe and effective adjuvant or steroid‐sparing agents are needed. In this retrospective observational study with a follow‐up extending to 16 years (mean: 4 years), 60% (9/15) of all patients with MMP were lesion‐free under oral steroid therapy combined with a second immunosuppressant agent. Colchicine was the most effective, clearing from at least one individual mucosal site lesions in 67% (8/12) of patients. Colchicine may be suggested as a first‐line corticosteroid‐sparing regimen in the management of MMP.